Fighting COVID-19
As a research-driven company, we are part of the collective effort in fighting COVID-19. Boehringer Ingelheim does not develop human vaccines; however, drawing from our different areas of expertise, we engage in a number of activities to find medical solutions to this pandemic, working closely with academic researchers, international institutions and others in the pharma industry. As early as January 15, we started to consider how Boehringer Ingelheim could best help. The two key questions in the very beginning were: what expertise do we have, and how can we contribute to protect people and treat patients? The answer is: quite a lot. Learn more about our engagement in the fight against COVID-19:
Overview of initiatives
The development of vaccines will enable the immunization of a large part of the population. However, people who are particularly at risk of falling seriously ill or who have already been infected will need other treatment options. Therefore, we also need other approaches to fight the disease and save patients’ lives.
Related Content
Our work with the Bill and Melinda Gates Foundation
